Drug Trial Radar · NCT07226232
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Aug 3, 2026
Primary completion
Dec 2, 2030
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Nov 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Conditions
- Major Depression
Interventions
PsilocybinDrug
Psilocybin comparator dose
PsilocybinDrug
Psilocybin Intervention Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Asberg Rating Scale (MADRS)Time frame: 2 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Birmingham VA Medical Center, Birmingham, AL
Birmingham, Alabama · Recruiting
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama · Recruiting
VA Portland Health Care System, Portland, OR
Portland, Oregon · Recruiting
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania · Recruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.